Robert Winn

Dr. Robert Winn

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Biology
Verified
Journal Article
Open access
PDF file
KCKristian Alissa Choate
Kristian Alissa Choate
EPEvan Pratt
Evan Pratt
MJMatthew Jennings
Matthew Jennings
RWRobert J. Winn
Robert J. Winn
PMPaul Barrie Mann
Paul Barrie Mann
In 2021, the World Health Organization classified isocitrate dehydrogenase (IDH) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an IDH mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. IDH enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of IDH mutations in gliomas as well as current diagnostic techniques.

7 December 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JLJohnathan E. Lawrence
Johnathan E. Lawrence
CSChristopher J. Steele
Christopher J. Steele
RRRichard A. Rovin
Richard A. Rovin
RBRobert J. Belton
Robert J. Belton
RWRobert J. Winn
Robert J. Winn

7 May 2004 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PDF file
RWRobert Winn
Robert Winn
SLSharon Laura
Sharon Laura
CDCharles Douglas
Charles Douglas
PDPatricia Davidson
Patricia Davidson
JGJonathan Gani
Jonathan Gani

4 March 2014 in ISRN Surgery
Verified
Journal Article
Open access
PDF file
JLJohnathan E. Lawrence
Johnathan E. Lawrence
APAshish S. Patel
Ashish S. Patel
RRRichard A. Rovin
Richard A. Rovin
RBRobert J. Belton
Robert J. Belton
CBCatherine E. Bammert
Catherine E. Bammert
RWRobert J. Winn
Robert J. Winn
Introduction. 5-Aminolevulinic Acid (5-ALA) is a precursor of heme synthesis. A metabolite, protoporphyrin IX (PpIX), selectively accumulates in neoplastic tissue including glioblastoma. Presurgical administration of 5-ALA forms the basis of fluorescence-guided resection (FGR) of glioblastoma (GBM) tumors. However, not all gliomas accumulate sufficient quantities of PpIX to fluoresce, thus limiting the utility of FGR. We therefore developed an assay to determine cellular and pharmacological factors that impact PpIX fluorescence in GBM. This assay takes advantage of a GBM cell line engineered to express yellow fluorescent protein. Methods. The human GBM cell line U87MG was transfected with a YFP expression vector. After treatment with a series of 5-ALA doses, both PpIX and YFP fluorescence were measured. The ratio of PpIX to YFP fluorescence was calculated. Results. YFP fluorescence permitted the quantification of cell numbers and did not interfere with 5-ALA metabolism. The PpIX/YFP fluorescence ratio provided accurate relative PpIX levels, allowing for the assessment of PpIX accumulation in tissue. Conclusion. Constitutive YFP expression strongly correlates with cell number and permits PpIX quantification. Absolute PpIX fluorescence alone does not provide information regarding PpIX accumulation within the cells. Our research indicates that our PpIX/YFP ratio assay may be a promising model for in vitro 5-ALA testing and its interactions with other compounds during FGR surgery.

4 January 2012 in Neurology Research International
Verified
Journal Article
Open access
PDF file
JLJohnathan E. Lawrence
Johnathan E. Lawrence
NCNicholas J. Cook
Nicholas J. Cook
RRRichard Rovin
Richard Rovin
RWRobert J. Winn
Robert J. Winn
The hormone leptin has a variety of functions. Originally known for its role in satiety and weight loss, leptin more recently has been shown to augment tumor growth in a variety of cancers. Within gliomas, there is a correlation between tumor grade and tumor expression of leptin and its receptor. This suggests that autocrine signaling within the tumor microenvironment may promote the growth of high-grade gliomas. Leptin does this through stimulation of cellular pathways that are also advantageous for tumor growth and recurrence: antiapoptosis, proliferation, angiogenesis, and migration. Conversely, a loss of leptin expression attenuates tumor growth. In animal models of colon cancer and melanoma, a decline in the expression and secretion of leptin resulted in a reduction of tumor growth. In these models, positive mental stimulation through environmental enrichment decreased leptin secretion and improved tumor outcome. This review explores the link between leptin and glioblastoma.

7 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKristian Alissa Choate
Kristian Alissa Choate
EPEvan Pratt
Evan Pratt
MJMatthew Jennings
Matthew Jennings
RWRobert J. Winn
Robert J. Winn
PMPaul Barrie Mann
Paul Barrie Mann
In 2021, the World Health Organization classified isocitrate dehydrogenase (IDH) mutant gliomas as a distinct subgroup of tumors with genetic changes sufficient to enable a complete diagnosis. Patients with an IDH mutant glioma have improved survival which has been further enhanced by the advent of targeted therapies. IDH enzymes contribute to cellular metabolism, and mutations to specific catalytic residues result in the neomorphic production of D-2-hydroxyglutarate (D-2-HG). The accumulation of D-2-HG results in epigenetic alterations, oncogenesis and impacts the tumor microenvironment via immunological modulations. Here, we summarize the molecular, cellular, and clinical implications of IDH mutations in gliomas as well as current diagnostic techniques.